How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

2,367 results for

Cushing Response

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

41. Collecting Information About Treatment Results for Patients With Cushing's Syndrome

adding more. Collecting Information About Treatment Results for Patients With Cushing's Syndrome The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03364803 Recruitment Status : Recruiting First Posted : December 7, 2017 Last (...) Update Posted : October 24, 2018 See Sponsor: Memorial Sloan Kettering Cancer Center Information provided by (Responsible Party): Memorial Sloan Kettering Cancer Center Study Details Study Description Go to Brief Summary: The purpose of this study is to follow participants with Cushing's syndrome during the course of their routine care and to form a data registry to study long term participant outcomes. Condition or disease Intervention/treatment Cushing's Disease Cushing Syndrome Cushing Disease

2017 Clinical Trials

42. Health Status of the Patients Followed for a Disease of Cushing in the Region Large-West of 1990 to 2015

). Please remove one or more studies before adding more. Health Status of the Patients Followed for a Disease of Cushing in the Region Large-West of 1990 to 2015 (CUSHING) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier (...) : NCT03297892 Recruitment Status : Not yet recruiting First Posted : September 29, 2017 Last Update Posted : October 5, 2017 See Sponsor: University Hospital, Brest Information provided by (Responsible Party): University Hospital, Brest Study Details Study Description Go to Brief Summary: Cushing's disease is a rare disease that can reduce patients' expectations or quality of life, and for which predictive factors for cardiovascular mortality and recurrence are not well defined. The primary objective

2017 Clinical Trials

43. Cushing's Osteoporosis Specificities

Information provided by (Responsible Party): University Hospital, Clermont-Ferrand Study Details Study Description Go to Brief Summary: Osteoporosis induced by glucocorticoids excess constitutes the main cause of secondary osteoporosis. Most of data available are provided from cohort studies of patients treated by corticosteroids, affecting among 1% of population. In contrast, very few data on osteoporosis are available in the Cushing syndrome (CS), a rare disease affecting 1 or 2 million of inhabitants (...) Cushing's Osteoporosis Specificities Cushing's Osteoporosis Specificities - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Cushing's Osteoporosis Specificities (SOCS) The safety and scientific validity

2017 Clinical Trials

44. Targeting Iatrogenic Cushing's Syndrome With 11β-hydroxysteroid Dehydrogenase Type 1 Inhibition

or more studies before adding more. Targeting Iatrogenic Cushing's Syndrome With 11β-hydroxysteroid Dehydrogenase Type 1 Inhibition (TICSI) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03111810 Recruitment Status (...) Targeting Iatrogenic Cushing's Syndrome With 11β-hydroxysteroid Dehydrogenase Type 1 Inhibition Targeting Iatrogenic Cushing's Syndrome With 11β-hydroxysteroid Dehydrogenase Type 1 Inhibition - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one

2017 Clinical Trials

45. Activity of Abiraterone Acetate in the Management of Cushing's Syndrome in Patients With Adrenocortical Carcinoma

studies (100). Please remove one or more studies before adding more. Activity of Abiraterone Acetate in the Management of Cushing's Syndrome in Patients With Adrenocortical Carcinoma (ABACUS) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03145285 Recruitment Status : Active, not recruiting First (...) Activity of Abiraterone Acetate in the Management of Cushing's Syndrome in Patients With Adrenocortical Carcinoma Activity of Abiraterone Acetate in the Management of Cushing's Syndrome in Patients With Adrenocortical Carcinoma - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved

2017 Clinical Trials

46. A rare case of an ACTH/CRH co-secreting midgut neuroendocrine tumor mimicking Cushing's disease (PubMed)

be compatible with Cushing's disease in ectopic CRH-secretion.High levels of CRH may induce hyperplasia of the corticotroph cells in the pituitary. This could be the cause of a preserved pituitary response to dexamethasone and CRH.Clinical features of ACTH-dependent hypercortisolism with rapid development of Cushing's syndrome, hyperpigmentation, high circulating levels of cortisol with associated hypokalemia, peripheral edema and proximal myopathy should be a warning flag of ectopic Cushing's syndrome (...) A rare case of an ACTH/CRH co-secreting midgut neuroendocrine tumor mimicking Cushing's disease Ectopic ACTH/CRH co-secreting tumors are a very rare cause of Cushing's syndrome and only a few cases have been reported in the literature. Differentiating between Cushing's disease and ectopic Cushing's syndrome may be particularly difficult if predominant ectopic CRH secretion leads to pituitary corticotroph hyperplasia that may mimic Cushing's disease during dynamic testing with both dexamethasone

Full Text available with Trip Pro

2017 Endocrinology, diabetes & metabolism case reports

47. The Cushing Reflex: Oliguria as a Reflection of an Elevated Intracranial Pressure (PubMed)

The Cushing Reflex: Oliguria as a Reflection of an Elevated Intracranial Pressure Oliguria is one of the clinical hallmarks of renal failure. The broad differential diagnosis is well known, but a rare cause of oliguria is intracranial hypertension (ICH). The actual knowledge to explain this relationship is scarce. Almost all literature is about animals where authors describe the Cushing reflex in response to ICH. We hypothesize that the Cushing reflex is translated towards the sympathetic

Full Text available with Trip Pro

2017 Case reports in nephrology

48. Comparison of hydrocortisone and prednisone in the glucocorticoid replacement therapy post-adrenalectomy of Cushing's Syndrome (PubMed)

Comparison of hydrocortisone and prednisone in the glucocorticoid replacement therapy post-adrenalectomy of Cushing's Syndrome Cushing's syndrome requires glucocorticoid replacement following adrenalectomy. Based on a simplified glucocorticoid therapy scheme and the peri-operative observation, we investigated its efficacy and safety up to 6 months post-adrenalectomy in this cohort study. We found the adrenocorticotropic hormone (ACTH) levels were normal post-adrenalectomy, and sufficient (...) to stimulate the recovery of the dystrophic adrenal cortex, thus exogenous supplemental ACTH might not be necessary. Patients were grouped by oral reception of either hydrocortisone or prednisone since day 2 post-adrenalectomy. Both groups had similar baseline responses to adrenalectomy, regarding the correction of hypertension (10/15 vs.12/19), hyperglycemia (6/11 vs. 7/10), and hypokalemia (12/12 vs. 11/11). Most patients lost weight (17/20 vs. 20/22). Both groups reported significant improvement

Full Text available with Trip Pro

2017 Oncotarget

49. The Eosinophil Count Tends to Be Negatively Associated with Levels of Serum Glucose in Patients with Adrenal Cushing Syndrome (PubMed)

The Eosinophil Count Tends to Be Negatively Associated with Levels of Serum Glucose in Patients with Adrenal Cushing Syndrome Cushing syndrome is characterized by glucose intolerance, cardiovascular disease, and an enhanced systemic inflammatory response caused by chronic exposure to excess cortisol. Eosinopenia is frequently observed in patients with adrenal Cushing syndrome, but the relationship between the eosinophil count in peripheral blood and indicators of glucose level in patients (...) with adrenal Cushing syndrome has not been determined.A retrospective study was undertaken of the clinical and laboratory findings of 40 patients diagnosed with adrenal Cushing syndrome at Chungnam National University Hospital from January 2006 to December 2016. Clinical characteristics, complete blood cell counts with white blood cell differential, measures of their endocrine function, description of imaging studies, and pathologic findings were obtained from their medical records.Eosinophil composition

Full Text available with Trip Pro

2017 Endocrinology and Metabolism

50. Chronic in vivo exposure to glucocorticoids prolongs cellular lifespan: the case of Cushing's syndrome-patients' fibroblasts. (PubMed)

Chronic in vivo exposure to glucocorticoids prolongs cellular lifespan: the case of Cushing's syndrome-patients' fibroblasts. Glucocorticoid (GC) hypersecretion constitutes the major hormonal response to stress. In an effort to investigate the impact of a long-lasting exposure to high GC levels in vivo on cellular longevity, we have studied the lifespan of skin fibroblasts from patients suffering from Cushing's syndrome, who are characterised by chronic endogenous GC excess. Interestingly, we (...) the hypothesis that stress response may have beneficial consequences in cellular longevity, as well as in tissue homeostasis.

2017 Experimental Gerontology

51. Endocrine Cardiomyopathy in Cushing Syndrome: Response to Cyclic GMP PDE5 inhibitOrs

Endocrine Cardiomyopathy in Cushing Syndrome: Response to Cyclic GMP PDE5 inhibitOrs Endocrine Cardiomyopathy in Cushing Syndrome: Response to Cyclic GMP PDE5 inhibitOrs - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before (...) adding more. Endocrine Cardiomyopathy in Cushing Syndrome: Response to Cyclic GMP PDE5 inhibitOrs (ERGO) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT02611258 Recruitment Status : Recruiting First Posted : November 20

2015 Clinical Trials

52. A dangerous Cushing response in a child: neurogenic heart damage. (PubMed)

A dangerous Cushing response in a child: neurogenic heart damage. Cushing response, which acts to preserve cerebral blood flow by inducing arterial hypertension, could induce neurogenic heart damage through hyperactivation of autonomic nervous system. Most of clinical reports describe neurogenic heart damage as a self-limiting condition clinically characterized by electrocardiographic abnormalities in the setting of an acute neurologic insult. Here we describe a case of life-threatening cardiac (...) in the setting of an acute neurologic insult. Thus, Cushing response, which is a physiological mechanism of cerebral protection, could become a double-edged sword when massive sympathetic activation makes the myocardium stunned.

2014 American Journal of Emergency Medicine

53. Systematic review and meta-analysis of DDAVP test accuracy for the differentiation of Cushing disease from pseudo-Cushing

Systematic review and meta-analysis of DDAVP test accuracy for the differentiation of Cushing disease from pseudo-Cushing Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence

2018 PROSPERO

54. ACTH after 15 minutes distinguishes between Cushing's disease and ectopic Cushing's syndrome: A proposal for a short and simple CRH test. (PubMed)

ACTH after 15 minutes distinguishes between Cushing's disease and ectopic Cushing's syndrome: A proposal for a short and simple CRH test. The aim of the present study was to validate criteria of corticotropin-releasing hormone (CRH) stimulation and 8 mg dexamethasone suppression (high-dose dexamethasone suppression, HDDS) to distinguish the etiology of ACTH-dependent Cushing's syndrome.We retrospectively analyzed cortisol and ACTH after the injection of 100 μg human CRH in confirmed Cushing's (...) disease (CD, n=78) and confirmed ectopic Cushing's syndrome (ECS, n=18). Cortisol and ACTH increase (in percentage above basal (%B)) at each time point, maximal increase (Δmax %B), and area under the curve (AUC %B) were analyzed using receiver operator characteristics (ROC) curve analyses. Cortisol suppression (%B) after 8 mg of dexamethasone was evaluated as a supplementary criterion.An increase in ACTH of ≥ 43%B at 15 min after CRH was the strongest predictor of CD, with a positive likelihood ratio

Full Text available with Trip Pro

2015 European Journal of Endocrinology

55. Systemic Sarcoidosis Unmasked by Cushing's Disease Surgical Treatment (PubMed)

Systemic Sarcoidosis Unmasked by Cushing's Disease Surgical Treatment Diseases responsive to glucocorticoids, like sarcoidosis, are rarely masked by Cushing's syndrome. An ACTH secreting pituitary adenoma is a possible cause of Cushing's syndrome and its resection can make a subclinical sarcoidosis clear. Only few cases of sarcoidosis following the treatment of hypercortisolism are reported in literature. We report a case of sarcoidosis after the resection of an ACTH secreting pituitary adenoma.

Full Text available with Trip Pro

2016 Case reports in medicine

56. Targeting the ERK pathway for the treatment of Cushing's disease (PubMed)

serve as a predictive biomarker of MEK-162 corticotroph tumor responsiveness. Additionally, MEK-162 treatment reduced TR4 protein expression and blocked recruitment of TR4 to bind its consensus site on the POMC promoter (-854bp to -637bp), elucidating multiple mechanisms to control TR4 corticotroph tumor actions. In a murine corticotroph tumor in vivo model of Cushing's disease, MEK-162 treatment inhibited tumor growth and reduced tumor-derived circulating plasma ACTH, and corticosterone levels (...) Targeting the ERK pathway for the treatment of Cushing's disease We recently demonstrated that the orphan nuclear receptor testicular receptor 4 (TR4) is a potent regulator of corticotroph tumor growth and hormone secretion. The Ras/Raf/MEK/ERK pathway is commonly overactivated in human tumors and we have demonstrated that corticotroph tumor TR4 is activated by ERK1/2-mediated phosphorylation. We evaluated effects of MEK-162, a selective, non-ATP-competitive allosteric inhibitor of MEK1/2

Full Text available with Trip Pro

2016 Oncotarget

57. Saliva Cortisol Measurement as a Screening Test for Suspicious Cushings Syndrome in Children.

or more studies before adding more. Saliva Cortisol Measurement as a Screening Test for Suspicious Cushings Syndrome in Children. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT02646553 Recruitment Status : Recruiting (...) First Posted : January 5, 2016 Last Update Posted : August 16, 2017 See Sponsor: Haukeland University Hospital Information provided by (Responsible Party): Haukeland University Hospital Study Details Study Description Go to Brief Summary: Cortisol overproduction ( Cushings syndrome) is a condition where the patient have a special fat distribution, with accumulation of fat around the abdomen and in the neck, with thinner limbs and weak musculature. The condition can be difficult to separate from

2016 Clinical Trials

58. Study to Evaluate CORT125134 in Patients With Cushing's Syndrome

in Patients With Cushing's Syndrome The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02804750 Recruitment Status : Completed First Posted : June 17, 2016 Last Update Posted : November 15, 2018 Sponsor: Corcept Therapeutics Information provided by (Responsible Party): Corcept Therapeutics Study Details Study (...) Responsible Party: Corcept Therapeutics ClinicalTrials.gov Identifier: Other Study ID Numbers: CORT125134-451 First Posted: June 17, 2016 Last Update Posted: November 15, 2018 Last Verified: November 2018 Individual Participant Data (IPD) Sharing Statement: Plan to Share IPD: Undecided Keywords provided by Corcept Therapeutics: Cushing's Syndrome Cushing's Disease Cushings Hypercortisolemia Cushingoid Type 2 Diabetes Impaired Glucose Intolerance Hypertension Adrenal Corticotrophic Hormone (ACTH

2016 Clinical Trials

59. The Accuracy of Late Night Urinary Free Cortisol/Creatinine and Hair Cortisol in Cushing's Syndrome Diagnosis

(100). Please remove one or more studies before adding more. The Accuracy of Late Night Urinary Free Cortisol/Creatinine and Hair Cortisol in Cushing's Syndrome Diagnosis The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier (...) The Accuracy of Late Night Urinary Free Cortisol/Creatinine and Hair Cortisol in Cushing's Syndrome Diagnosis The Accuracy of Late Night Urinary Free Cortisol/Creatinine and Hair Cortisol in Cushing's Syndrome Diagnosis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies

2016 Clinical Trials

60. Biomarker Expression in Patients With ACTH-Dependent Cushing's Syndrome Before and After Surgery

or more studies before adding more. Biomarker Expression in Patients With ACTH-Dependent Cushing's Syndrome Before and After Surgery The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02922257 Recruitment Status : Completed First Posted : October 4, 2016 Last Update Posted : January 24, 2019 Sponsor (...) : Corcept Therapeutics Information provided by (Responsible Party): Corcept Therapeutics Study Details Study Description Go to Brief Summary: This study will investigate the potential for FK506 binding protein 5 (FKBP5) (and other gene expression markers, for example pentraxin 3 [PTX-3], serum/glucocorticoid regulated kinase 1 [SGK1], and glycogen synthase kinase 3 beta [GSK3b]) to be developed as a biomarker for use in diagnosis of Cushing's syndrome, assessment of effectiveness of medical or surgical

2016 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>